Traynor Capital Management Inc. raised its position in Bristol-Myers Squibb Co. (NYSE:BMY) by 0.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,071 shares of the biopharmaceutical company’s stock after buying an additional 4 shares during the period. Traynor Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $447,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Bartlett & Co. LLC increased its position in Bristol-Myers Squibb by 8.5% in the second quarter. Bartlett & Co. LLC now owns 443,982 shares of the biopharmaceutical company’s stock worth $32,655,000 after buying an additional 34,803 shares in the last quarter. Solaris Asset Management LLC increased its position in Bristol-Myers Squibb by 3.5% in the second quarter. Solaris Asset Management LLC now owns 2,244 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 75 shares in the last quarter. Aviance Capital Management LLC acquired a new position in Bristol-Myers Squibb during the second quarter worth approximately $988,000. Artemis Investment Management LLP acquired a new position in Bristol-Myers Squibb during the second quarter worth approximately $14,491,000. Finally, Boston Advisors LLC increased its position in Bristol-Myers Squibb by 247.2% in the second quarter. Boston Advisors LLC now owns 561,927 shares of the biopharmaceutical company’s stock worth $41,330,000 after buying an additional 400,099 shares in the last quarter. Institutional investors own 72.87% of the company’s stock.
Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded up 1.44% during mid-day trading on Tuesday, reaching $50.05. 8,773,340 shares of the company’s stock were exchanged. The firm has a market cap of $83.63 billion, a P/E ratio of 29.27 and a beta of 0.75. The company has a 50 day moving average price of $54.57 and a 200 day moving average price of $66.13. Bristol-Myers Squibb Co. has a 52-week low of $49.10 and a 52-week high of $77.12.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The business earned $4.90 billion during the quarter, compared to analysts’ expectations of $4.60 billion. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.53 EPS. Analysts forecast that Bristol-Myers Squibb Co. will post $2.63 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Shareholders of record on Friday, October 7th will be given a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 annualized dividend and a yield of 3.04%. Bristol-Myers Squibb’s payout ratio is currently 87.36%.
BMY has been the subject of several recent analyst reports. Credit Suisse Group AG reiterated a “hold” rating and issued a $58.00 target price on shares of Bristol-Myers Squibb in a research note on Monday. Goldman Sachs Group Inc. downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $75.00 target price for the company. in a research note on Thursday, October 13th. Barclays PLC reiterated an “equal weight” rating on shares of Bristol-Myers Squibb in a research note on Wednesday, October 12th. SunTrust Banks Inc. reiterated a “hold” rating and issued a $62.00 target price (down from $68.00) on shares of Bristol-Myers Squibb in a research note on Monday, October 10th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $69.00 target price on shares of Bristol-Myers Squibb in a research note on Sunday, October 9th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $69.06.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 21,600 shares of the stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the completion of the sale, the director now owns 334,499 shares of the company’s stock, valued at approximately $19,022,958.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.24% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.